Yu X, Harden K, Gonzalez LC, et al. The surface protein TIGIT suppresses T cell activation by promoting the
generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009;10(1):48-57.
Stanietsky N, Simic H, Arapovic J, et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell
cytotoxicity. Proc Natl Acad Sci U S A. 2009;106(42):17858-17863.
Joller N, Lozano E, Burkett PR, et al. Treg cells expressing the coinhibitory molecule TIGIT selectively
inhibit proinflammatory Th1 and Th17 cell responses. Immunity. 2014;40(4):569-581.
Bottino C, Castriconi R, Pende D, et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface
ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med. 2003;198(4):557-567.
Lozano E, Dominguez-Villar M, Kuchroo V, Hafler DA. The TIGIT/CD226 axis regulates human T cell function. J
Immunol. 2012;188(8):3869-3875.
Goding SR, Wilson KA, Xie Y, et al. Restoring immune function of tumor-specific CD4+ T cells during
recurrence of melanoma. J Immunol. 2013;190(9):4899-4909.
Johnston RJ, Comps-Agrar L, Hackney J, et al. The immunoreceptor TIGIT regulates antitumor and antiviral
CD8+ T cell effector function. Cancer Cell. 2014;26(6):923-937.
Chauvin J-M, Pagliano O, Fourcade J, et al. TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in
melanoma patients. J Clin Invest. 2015;125(5):2046-2058.
Joller N, Hafler JP, Brynedal B, et al. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J
Immunol. 2011;186(3):1338-1342.
Hung AL, Maxwell R, Theodros D, et al. TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity
and survival in GBM. Oncoimmunology. 2018;7(8):e1466769. doi:10.1080/2162402X.2018. 1466769.